ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

zalifrelimab

Also written as “Zalifrelimab”, “UGN-301” and “Balstilimab + Zalifrelimab”.

Its studies are mostly in Uterine Cervical Neoplasms · Prostatic Neoplasms · Non-Muscle Invasive Bladder Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 3 companies.

Drug pageZalifrelimab: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Feb 12, 20166 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agenusits history only40 open or runningphase 2since Feb 12, 2016Feb 12, 2016none ahead
ImmunoGenesis11 open or runningphase 2since Jan 9, 2025Jan 9, 2025Oct 2027phase 2 · NCT06782555
UroGen Pharmaits history only10 open or runningphase 1since May 5, 2022May 5, 2022none ahead

Also a collaborator on its studies: Betta Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of ImmunoGenesis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2018Named zalifrelimabINNProposed as its International Nonproprietary Name in WHO's List 120 · before, UGN-301
  2. Jan 9, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT06782555 · 71 enrolled · United States

Ahead

  1. Oct 2027Primary completion: phase 2 study in Prostatic NeoplasmsNCT06782555

TargetBeta

CTLA4 →read by rule
“A recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities”NCIt, by rule
“Cytotoxic T-lymphocyte protein 4 inhibitor”ChEMBL 37, by rule

Other programs on CTLA4

ProgramCompanyFurthest phaseStudies
tremelimumabruleAstraZenecaphase 347
cadonilimabruleAkesophase 345
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
Anti-CTLA-4 Monoclonal Antibody SHR-8068ruleJiangsu HengRui Medicinephase 316
erfonrilimabruleAlphamab Oncologyphase 314
Anti-CTLA-4 Monoclonal Antibody IBI310ruleInnovent Biologicsphase 311
gotistobartruleoncoc4-incphase 35
porustobartruleharbour-biomed-guangzhou-co-ltdphase 25
lorigerlimabruleMacroGenicsphase 24
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
GB268ruleeddingpharm-zhuhai-co-ltdphase 22

Studies

The one study ImmunoGenesis leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06782555Prostatic Neoplasms · United States2Active, not recruitingOct 202771

How it is read

Names in the registry

  • “Zalifrelimab”, 3 entries
  • “UGN-301”, 1 entry
  • “Balstilimab + Zalifrelimab”, 1 entry
  • “AGEN1884 in combination with pembrolizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.